Post-earnings recap
Reported
Mon, Aug 7, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a 2.65% decline in stock price. The lack of revenue figures and management commentary leaves investors without additional context for the results. Overall, the disappointing EPS may raise concerns about the company's financial health going forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.96 | N/A | -66.38% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.